Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Pembrolizumab in Renal Cell Carcinoma: NCT05733715 Clinical Landscape Report 2026
16 October 2026
NCT05733715 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cadonilimab in Recurrent Glioblastoma: NCT05737368 Clinical Landscape Report 2026
16 October 2026
NCT05737368 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
177Lu-NeoBOMB1 in Recurrent Glioblastoma: NCT05739942 Clinical Landscape Report 2026
16 October 2026
NCT05739942 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fosigotifator in Amyotrophic Lateral Sclerosis: NCT05740813 Clinical Landscape Report 2026
16 October 2026
NCT05740813 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium (89Zr) crefmirlimab berdoxam in Renal Cell Carcinoma: NCT05744128 Clinical Landscape Report 2026
16 October 2026
NCT05744128 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Renal Cell Carcinoma: NCT05738694 Clinical Landscape Report 2026
16 October 2026
NCT05738694 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Neoantigen peptide vaccine(Washington University School of Medicine) in Glioblastoma Multiforme: NCT05743595 Clinical Landscape Report 2026
16 October 2026
NCT05743595 clinical landscape for Glioblastoma Multiforme: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Chidamide in Advanced Triple-Negative Breast Carcinoma: NCT05747313 Clinical Landscape Report 2026
16 October 2026
NCT05747313 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Tauroursodeoxycholate sodium in Amyotrophic Lateral Sclerosis: NCT05753852 Clinical Landscape Report 2026
16 October 2026
NCT05753852 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tislelizumab in Metastatic Triple-Negative Breast Carcinoma: NCT05746728 Clinical Landscape Report 2026
16 October 2026
NCT05746728 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Pembrolizumab in Ovarian Cancer: NCT05746897 Clinical Landscape Report 2026
16 October 2026
NCT05746897 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cannabidiol in Glioblastoma: NCT05753007 Clinical Landscape Report 2026
16 October 2026
NCT05753007 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.